

Thomas Mercher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7924116/publications.pdf>

Version: 2024-02-01

67
papers

9,220
citations

134610

34
h-index

116156

66
g-index

76
all docs

76
docs citations

76
times ranked

11456
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening of ETO2-GLIS2-induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabg9455.	4.7	9
2	Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	11
3	Molecular Landscapes and Models of Acute Erythroleukemia. <i>HemaSphere</i> , 2021, 5, e558.	1.2	2
4	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. <i>Blood</i> , 2020, 136, 698-714.	0.6	28
5	Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia. <i>Nature Communications</i> , 2020, 11, 2807.	5.8	18
6	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. <i>Blood Cancer Journal</i> , 2020, 10, 38.	2.8	7
7	The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. <i>HemaSphere</i> , 2020, 4, e319.	1.2	8
8	Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3307-3318.	3.2	28
9	SPEN integrates transcriptional and epigenetic control of X-inactivation. <i>Nature</i> , 2020, 578, 455-460.	13.7	146
10	Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. <i>Frontiers in Pediatrics</i> , 2019, 7, 401.	0.9	27
11	A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. <i>Cancer Discovery</i> , 2019, 9, 796-811.	7.7	30
12	Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. <i>Cancer Discovery</i> , 2019, 9, 1736-1753.	7.7	37
13	Transformation Mechanisms of the Nfia-ETO2 Fusion Gene Associated with Pediatric Pure Acute Erythroleukemia. <i>Blood</i> , 2019, 134, 532-532.	0.6	1
14	AIF loss deregulates hematopoiesis and reveals different adaptive metabolic responses in bone marrow cells and thymocytes. <i>Cell Death and Differentiation</i> , 2018, 25, 983-1001.	5.0	49
15	B-cell tumor development in Tet2-deficient mice. <i>Blood Advances</i> , 2018, 2, 703-714.	2.5	37
16	Chromosomal Translocation Formation Is Sufficient to Produce Fusion Circular RNAs Specific to Patient Tumor Cells. <i>IScience</i> , 2018, 5, 19-29.	1.9	15
17	Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models. <i>Blood Advances</i> , 2018, 2, 1616-1627.	2.5	9
18	Crispri-Based Screening of Clustered Regulatory Elements Reveals Novel Leukemia Dependencies. <i>Blood</i> , 2018, 132, 654-654.	0.6	0

#	ARTICLE	IF	CITATIONS
19	ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia. <i>Cancer Cell</i> , 2017, 31, 452-465.	7.7	60
20	Pediatric Acute Megakaryoblastic Leukemia: Multitasking Fusion Proteins and Oncogenic Cooperations. <i>Trends in Cancer</i> , 2017, 3, 631-642.	3.8	18
21	Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1345351.	0.3	10
22	Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 425-427.	0.3	14
23	DNMT3AR882H mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. <i>Leukemia</i> , 2016, 30, 1388-1398.	3.3	67
24	ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia. <i>Blood</i> , 2016, 128, 572-572.	0.6	0
25	Recurrent TET2 mutations in adult T cell leukemia. <i>Retrovirology</i> , 2014, 11, .	0.9	1
26	JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. <i>Leukemia</i> , 2014, 28, 338-348.	3.3	137
27	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. <i>Cancer Discovery</i> , 2014, 4, 1088-1101.	7.7	213
28	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2014, 32, 2084-2097.	1.4	34
29	STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. <i>Cancer Research</i> , 2013, 73, 373-384.	0.4	30
30	Ikars inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. <i>Blood</i> , 2013, 121, 2440-2451.	0.6	48
31	Developmental changes in human megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1730-1741.	1.9	68
32	TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. <i>EMBO Journal</i> , 2013, 32, 645-655.	3.5	411
33	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	1.7	50
34	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. <i>Nature Communications</i> , 2012, 3, 717.	5.8	122
35	Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. <i>Journal of Experimental Medicine</i> , 2012, 209, 2017-2031.	4.2	87
36	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. <i>Blood</i> , 2012, 120, 4846-4849.	0.6	89

#	ARTICLE	IF	CITATIONS
37	Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. <i>Cell</i> , 2012, 150, 575-589.	13.5	136
38	A functional role for the histone demethylase UTX in normal and malignant hematopoietic cells. <i>Experimental Hematology</i> , 2012, 40, 487-498.e3.	0.2	22
39	TET2, a tumor suppressor in hematological disorders. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 173-177.	3.3	16
40	Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. <i>Blood</i> , 2011, 118, 1264-1273.	0.6	61
41	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	7.7	792
42	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 276.	7.7	3
43	RUNX1-Induced Silencing of Non-Muscle Myosin IIB (MYH10) Is Required for Megakaryocyte Polyploidization. <i>Blood</i> , 2011, 118, 1308-1308.	0.6	0
44	TET2 Favors Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. <i>Blood</i> , 2011, 118, 2418-2418.	0.6	0
45	Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. <i>Cancer Cell</i> , 2010, 17, 584-596.	7.7	324
46	Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. <i>Leukemia</i> , 2010, 24, 642-645.	3.3	58
47	Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. <i>Haematologica</i> , 2010, 95, 1642-1650.	1.7	14
48	JAK3: A two-faced player in hematological disorders. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2376-2379.	1.2	76
49	Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. <i>Blood</i> , 2009, 113, 2746-2754.	0.6	76
50	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. <i>Journal of Clinical Investigation</i> , 2009, 119, 852-64.	3.9	80
51	Notch Signaling Specifies Megakaryocyte Development from Hematopoietic Stem Cells. <i>Cell Stem Cell</i> , 2008, 3, 314-326.	5.2	117
52	OTT-MAL Is a Deregulated Activator of Serum Response Factor-Dependent Gene Expression. <i>Molecular and Cellular Biology</i> , 2008, 28, 6171-6181.	1.1	38
53	Ott1 (Rbm15) has pleiotropic roles in hematopoietic development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6001-6006.	3.3	72
54	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. <i>Blood</i> , 2007, 110, 323-333.	0.6	44

#	ARTICLE	IF	CITATIONS
55	Notch Signaling Induces Megakaryocytic Cell Fate.. Blood, 2007, 110, 200-200.	0.6	0
56	Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 2006, 107, 4274-4281.	0.6	448
57	JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood, 2006, 108, 2770-2779.	0.6	104
58	CEBPA dosage in leukemogenesis. Blood, 2006, 108, 3234-3234.	0.6	0
59	Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 2006, 10, 65-75.	7.7	295
60	MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Medicine, 2006, 3, e270.	3.9	1,222
61	Ott1 (Rbm15) Is Essential for Pre-B Differentiation and Has an Inhibitory Role in Myeloid and Megakaryocytic Lineages.. Blood, 2006, 108, 784-784.	0.6	0
62	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7, 387-397.	7.7	2,695
63	Interaction of the Epstein-Barr Virus mRNA Export Factor EB2 with Human Spn Proteins SHARP, OTT1, and a Novel Member of the Family, OTT3, Links Spn Proteins with Splicing Regulation and mRNA Export. Journal of Biological Chemistry, 2005, 280, 36935-36945.	1.6	70
64	A novel real-time RT-PCR assay for quantification of OTT-MAL fusion transcript reliable for diagnosis of t(1;22) and minimal residual disease (MRD) detection. Leukemia, 2003, 17, 1193-1196.	3.3	21
65	Recurrence of OTT-MAL fusion in t(1;22) of infant AML-M7. Genes Chromosomes and Cancer, 2002, 33, 22-28.	1.5	56
66	A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia, 2001, 15, 1495-1504.	3.3	230
67	Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5776-5779.	3.3	213